Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Anorectal Melanoma

In: Noncutaneous Melanoma [Internet]. Brisbane (AU): Codon Publications; 2018 Mar. Chapter 6.
Affiliations
Free Books & Documents
Review

Anorectal Melanoma

Giovanni Paolino et al.
Free Books & Documents

Excerpt

Anorectal melanoma (AM) is a rare malignancy, characterized by aggressive behavior and a poor prognosis. AM is more frequent in female patients aged over 50 years. AM accounts for 0.4–1.6% of all melanomas, 23.8% of all mucosal melanomas, and 1% of all anorectal malignant tumors. There are many theories regarding AM pathogenesis. Some consider that AM may be related to oxidative stress in the region and/or to immunosuppression. Others propose that AM may derive from Schwannian neuroblastic cells or cells of the amine-precursor uptake and decarboxylation system of the gut. Assessment of pigmented lesions located on hidden areas is difficult. Together with late and nonspecific signs and symptoms which usually occur only in conjunction with large masses, diagnosis of these mucosal melanomas is often delayed. Most frequently, the signs and symptoms are obstruction, rectal bleeding, pain, or rectal tenesmus. There are various histological variants of AM: epithelioid, spindle cell, lymphoma-like, and pleomorphic. Surgery (abdominoperineal resection or local excision) is the most effective treatment for AM; however, this is not associated with improved overall survival. Recurrence is more frequent in cases of anorectal and rectal involvement when compared with anal-only involvement. There is currently no consensus about the most appropriate systemic treatment. The efficacy of some protocols previously used in patients with cutaneous melanomas is currently being studied in mucosal melanoma.

PubMed Disclaimer

References

    1. Schaefer T, Satzger I, Gutzmer R. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma. A retrospective analysis of 75 patients. Medicine (Baltimore). 2017 Jan;96(1):e5753. doi: 10.1097/MD.0000000000005753. - DOI - PMC - PubMed
    1. Parra RS, Almeida AL, Badiale BG, Moraes MM, Rocha JJ, Féres O. Melanoma of the anal canal. Clinics (Sao Paulo). 2010 Oct;65(10):1063–1065. doi: 10.1590/S1807-59322010001000026. - DOI - PMC - PubMed
    1. Micu E, Juzeniene A, Moan J. Comparison of the time and latitude trends of melanoma incidence in anorectal region and perianal skin with those of cutaneous malignant melanoma in Norway. J Eur Acad Dermatol Venereol. 2011 Dec;25(12):1444–9. doi: 10.1111/j.1468-3083.2011.04023.x. - DOI - PubMed
    1. Cagir B, Whiteford MH, Topham A, Rakinic J, Fry RD. Changing epidemiology of anorectal melanoma. Dis Colon Rectum. 1999;42:1203–1208. doi: 10.1007/BF02238576. - DOI - PubMed
    1. Postow MA, Hamid O, Carvajal RD. Mucosal melanoma: Pathogenesis, clinical behavior, and management. Curr Oncol Rep. 2012 Oct;14(5):441–8. doi: 10.1007/s11912-012-0244-x. - DOI - PubMed

LinkOut - more resources